The Business Times
SUBSCRIBERS

Name change, new ambitions for Biogen

Company has eye on drugs for Alzheimer's, ALS; CEO to drive drug development for some hardest-to-treat diseases

google-preferred-sourceAdd BT as a preferred source
Published Mon, Mar 23, 2015 · 09:50 PM

    New York

    BIOGEN IDEC Inc has seen its market value quadruple in three years to more than US$100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights.

    The Massachusetts-based company, which made headlines last week when it announced better-than-expected clinical trial results for its experimental Alzheimer's drug, aducanumab, said that it will drop Idec from its name as of Monday and adopt a new logo. The company merged with Idec Pharmaceuticals more than a decade ago.

    Copyright SPH Media. All rights reserved.

    Reuse this contentFeedback
    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More